Neoadjuvant accelerated concomitant boost radiotherapy and multidrug chemotherapy in locally advanced rectal cancer: A dose-escalation study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 5, 2012, Pages 424-431

  Caravatta, Luciana ^a   Picardi, Vincenzo ^a   Tambaro, Rosa ^b   Padula, Gilbert D A ^c   Macchia, Gabriella ^a   Deodato, Francesco ^a   Massaccesi, Mariangela ^a   Pacelli, Fabio ^d   Berardi, Stefano ^d   Ridolfini, Marco Pericoli ^d   Di Filippo, Loredana ^e   Fabrizio, Giovanni ^f   Ingrosso, Marcello ^d   Cellini, Numa ^g   Valentini, Vincenzo ^g   Morganti, Alessio G ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c Saint Mary's Health Care   (United States)

^d Catholic University   (United States)

^e Pathology Unit   (United States)

^f Surgery Unit   (Italy)

^g FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

accelerated radiotherapy; neoadjuvant treatment; oxaliplatin; raltitrexed; rectal carcinoma

Indexed keywords

OXALIPLATIN; RALTITREXED;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ANEMIA; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG DOSE REDUCTION; DRUG SAFETY; DYSESTHESIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; NEPHROTOXICITY; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; RECTUM CANCER; RECTUM SURGERY; SKIN TOXICITY; THROMBOCYTOPENIA;

EID: 84866743720     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31821a5844     Document Type: Article

References (48)

1. Ferlay J, Autier P, Boniol M, et al. Estimates of cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581-592.
2. Peeters KC, Marijnen CA, Nagtegaal ID, et al. Dutch Colorectal Cancer Group the TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246:693-701.
3. Martling A, Holm T, Johansson H, et al. The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: long-term follow-up of a population-based study. Cancer. 2001;92:896-902.
4. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resect-able rectal cancer. N Engl J Med. 2001;345:638-646.
5. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Sphincter preservation following pre-operative radiotherapy for rectal cancer: report of randomized trial comparing short-term radiotherapy versus conventionally fractionated radiochemotherapy. Radiother Oncol. 2004;72:15-24.
6. Valentini V, Beets-Tan R, Borras JM, et al. Evidence and research in rectal cancer. Radiother Oncol. 2008;87:449-474.
7. Munro AJ, Bentley A. Adjuvant radiotherapy in operable rectal cancer: a systematic review. Sem Colon Rectal Surg. 2002;13: 31-42.
8. Glimelius B. Pre-or postoperative radiotherapy in rectal cancer-more to learn? Radiother Oncol. 2001;61:1-5.
9. Marijnen CAM, Peeters KCMJ, Putter H, et al. Long term results, toxicity and quality of life in the TME trial. Radiother Oncol. 2004;73:S127.
10. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-1740.
11. Bosset JF, Collette L, Calais G, et al. EORTC Radiotherapy Group Trial 22921: chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114-1123.
12. Gérard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24: 4620-4625.
13. Aschele C, Pinto C, Cordio S, et al. Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial. J Clin Oncol. 2009;27:18 S.
14. Valentini V, Aristei C, Glimelius B, et al. Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol. 2009;92:148-163.
15. Martoni A, Mini E, Pinto C, et al. Oxaliplatin plus raltitrexed in the treatment of patients with advanced colorectal cancer: a phase II study. Anticancer Res. 2003;23:687-691.
16. Gambacorta MA, Valentini V, Coco C, et al. Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: phase I and II studies. Int J Radiat Oncol Biol Phys. 2004;60:139-148.
17. Valentini V, Coco C, Minsky BD, et al. Randomized, multicenter, phase IIb study of preoperative chemoradiotherapy in T3 mid-distal rectal cancer: raltitrexed+oxaliplatin+radiotherapy versus cisplatin+5- fluorouracil+radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:403-412.
18. Terry NH, Meistrich ML, Roubein LD, et al. Cellular kinetics in rectal cancer. Br J Cancer. 1995;72:435-441.
19. Movsas B, Diratzouian H, Hanlon A, et al. Phase II trial of preoperative chemoradiation with a hyperfractionated boost in locally advanced rectal cancer. Am J Clin Oncol. 2006;29: 435-441.
20. Allal AS, Bieri S, Bründler MA, et al. Preoperative hyperfractio-nated radiotherapy for locally advanced rectal cancers: a phase I-II trial. Int J Radiat Oncol Biol Phys. 2002;54:1076-1081.
21. Mohiuddin M, Winter K, Mitchel E, et al. Randomised phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol. 2006;24:650-655.
22. Janjian NA, Crane CN, Feig BW, et al. Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2000;47:713-718.
23. Myerson RJ, Valentini V, Birnbaum EH, et al. A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma. Int J Radiat Oncol Biol Phys. 2001;50:1299-1308.
24. Ballonoff A, Kavanagh B, McCarter M, et al. Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial. Am J Clin Oncol. 2008;31:264-270.
25. Krishnan S, Janjan NA, Skibber JM, et al. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006;66:762-771.
26. Gérard JP, Chapet O, Nemoz C, et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with highdose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol. 2003;21:1119-1124.
27. Kim DY, Kim TH, Jung KH, et al. Preoperative chemoradiother-apy with concomitant small field boost irradiation for locally advanced rectal cancer: a multi-institutional phase II study (KROG 04-01). Dis Colon Rectum. 2006;49:1684-1691.
28. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
29. Oken MM, Creech RH, Thormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
30. Arbuck SG. Workshop on phase I study design: ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996. Ann Oncol. 1996;7:567-573.
31. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341-1346.
32. Colevas AD, Setser A. The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials. J Clin Oncol 2004; ASCO Annual Meeting Proceedings (Post-Meeting Edition) 14S: 6098.
33. Pijls-Johannesma M, van Mastrigt G, Hahn SM et al. A systematic methodology review of phase I radiation dose escalation trials. Radiother Oncol. 2010;95:135-141.
34. Glynne-Jones R, Sebag-Montefiore D, Maughan TS, et al. A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol. 2006;17:50-56.
35. Morganti AG, Balducci M, Salvati M, et al. A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT in combination with temozolomide in patients with glioblastoma. Int J Radiat Oncol Biol Phys. 2010;77:92-97.
36. Capirci C, Polico C, Mandoliti G. Dislocation of small bowel volume within box pelvic treatment fields, using new ''up down table'' device. Int J Radiat Oncol Biol Phys. 2001;51:465-473.
37. Roels S, Duthoy W, Haustermans K, et al. Definition and delineation of the clinical target volume for rectal cancer. Int J Radiat Oncol Biol Phys. 2006;65:1129-1142.
38. International Commission on Radiation Units and Measurements, ICRU report 62: Prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50). Bethesda 1999.
39. Luna-Pérez P, Trejo-Valdivia B, Labastida S, et al. Prognostic factors in patients with locally advanced rectal adenocarcinoma treated with preoperative radiotherapy and surgery. World J Surg. 1999;23:1069-1074.
40. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
41. Sculpher M, Palmer MK, Heyes A. Costs incurred by patients undergoing advanced colorectal cancer therapy: a comparison of raltitrexed and fluorouracil plus folinic acid. Pharmacoeconomics. 2000;17:361-370.
42. Valentini V, Doglietto GB, Morganti AG, et al. Preoperative chemoradiation with raltitrexed (''Tomudex'') for T2/N+ and T3/ N+ rectal cancers: a phase I study. Eur J Cancer. 2001;37: 2050-2055.
43. Gambacorta MA, Valentini V, Coco C, et al. Sphincter preservation in four consecutive phase II studies of preoperative chemo radiation: analysis of 247 T3 rectal cancer patients. Tumori. 2007;93:160-169.
44. Gérard J-P, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase II trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28:1638-1644.
45. Aschele CP, Cordio S, Rosati G, et al. Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial. J Clin Oncol. 2009;27:170s.
46. Pucciarelli S, Toppan P, Friso ML, et al. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome. Dis Colon Rectum. 2004;47:1798-1807.
47. Capirci C, Valentini V, Cionini L, et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: longterm analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys. 2008;72:99-107.
48. Vecchio FM, Valentini V, Minsky BD, et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys. 2005;62:752-760.